Oregon Public Employees Retirement Fund Has $9.88 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Oregon Public Employees Retirement Fund raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,184 shares of the pharmaceutical company’s stock after acquiring an additional 100 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Vertex Pharmaceuticals were worth $9,876,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of VRTX. Price T Rowe Associates Inc. MD raised its stake in shares of Vertex Pharmaceuticals by 72.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock worth $1,414,331,000 after buying an additional 1,226,527 shares during the last quarter. Nuveen LLC bought a new position in Vertex Pharmaceuticals during the first quarter worth about $484,053,000. Jennison Associates LLC boosted its holdings in Vertex Pharmaceuticals by 17.2% during the first quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company’s stock worth $2,454,373,000 after buying an additional 744,680 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Vertex Pharmaceuticals by 28.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,775,194 shares of the pharmaceutical company’s stock worth $860,650,000 after buying an additional 398,460 shares during the period. Finally, Alyeska Investment Group L.P. increased its stake in shares of Vertex Pharmaceuticals by 456.9% in the 1st quarter. Alyeska Investment Group L.P. now owns 431,804 shares of the pharmaceutical company’s stock valued at $209,347,000 after acquiring an additional 354,269 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on VRTX. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Leerink Partners raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price objective for the stock from $458.00 to $456.00 in a research note on Thursday, September 25th. Weiss Ratings restated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. Guggenheim cut their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Finally, BMO Capital Markets set a $530.00 target price on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $494.38.

Vertex Pharmaceuticals Trading Down 1.7%

NASDAQ VRTX opened at $407.79 on Monday. The company has a market cap of $104.55 billion, a PE ratio of 29.15 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The stock has a 50 day moving average of $393.91 and a 200-day moving average of $438.74.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter last year, the company posted ($12.83) earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bruce I. Sachs acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were purchased at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.